Document Detail


Synthetic adjuvants for vaccine formulations: phytol derivatives.
MedLine Citation:
PMID:  23293963     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: The development of vaccines is considered a key milestone in preventive medicine. There is no comparable cost-effective means for controlling or eradicating infectious diseases. Yet, a persistent societal problem is the concern about vaccine's safety and long-term effects, and this caters to detractors of vaccination. Pathogen-derived antigen(s) as well as adjuvants/immunostimulants are essential for vaccine efficacy. Currently, adjuvant selection is largely empirical, but the mechanism underlying adjuvanticity is beginning to unravel. This should help develop more defined or targeted adjuvants.
AREAS COVERED: This review provides a brief account and analysis of the host immune parameters modulated by some commonly used as well as new adjuvants, including phytol-based diterpenoids. The major efforts are directed toward evaluating their relative safety and immunomodulatory efficiency, compared to known synthetic and natural adjuvants. Concerns for adverse pathological inflammation and autoimmunity are also addressed.
EXPERT OPINION: The phytol-based adjuvants hold great promise for improving vaccine efficacy, as they cause little or no persistent inflammation, but are highly effective in stimulating a multifaceted immune response, characterized by proficient recruitment of immune cells, generation of antibody and immunological memory, and activation of both Th1 and Th2 responses. Future focus will be on developing cocktail adjuvants to activate the complement system, mobilize follicular T helper cells as well as NKT and γδ T cells and activate cross-presenting dendritic cells to stimulate CD8(+) effector T cells.
Authors:
Swapan K Ghosh; Roshni Roy Chowdhury
Related Documents :
23447033 - Knowledge, attitudes and beliefs of health care workers towards influenza vaccination.
23845813 - The state-of-the-art of approved and under-development cholera vaccines.
20096763 - Beta-glucan-crm197 conjugates as candidates antifungal vaccines.
Publication Detail:
Type:  Journal Article; Review     Date:  2013-01-08
Journal Detail:
Title:  Expert opinion on drug delivery     Volume:  10     ISSN:  1744-7593     ISO Abbreviation:  Expert Opin Drug Deliv     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-15     Completed Date:  2013-05-17     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101228421     Medline TA:  Expert Opin Drug Deliv     Country:  England    
Other Details:
Languages:  eng     Pagination:  437-50     Citation Subset:  IM    
Affiliation:
Indiana State University, Department of Biology, Terre Haute, IN 47809, USA. Swapan.Ghosh@indstate.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / chemistry*
Chemistry, Pharmaceutical*
Diterpenes / chemistry
Humans
Phytol / analogs & derivatives,  chemistry*
T-Lymphocytes, Helper-Inducer / immunology
Vaccination
Vaccines / chemistry*,  immunology
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Diterpenes; 0/Vaccines; 150-86-7/Phytol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hepatocyte growth factor activator inhibitor type 2 (HAI-2) modulates hepcidin expression by inhibit...
Next Document:  Single Molecule Force Spectroscopy Identifies a Small Cold Shock Protein as Being Mechanically Robus...